ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2025
Trends in Radiation Use from 2004 to 2020 among Adolescents and Young Adults with Hodgkin Lymphoma.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
17 authors.
Funding
Abstract
backgroundHodgkin lymphoma has excellent survival rates in adolescents and young adults (AYA, diagnosed between ages 15 and 39 years). However, survivors are at risk of treatment-related late effects. Whereas radiotherapy (RT) de-escalation/omission has emerged as an approach to minimize late effects, no prior studies have evaluated RT use over time in AYAs with Hodgkin lymphoma.
methodsUsing the National Cancer Database, we identified 40,717 AYAs diagnosed with Hodgkin lymphoma between 2004 and 2020. Differences in sociodemographic and clinical variables were assessed using a two-sample two-sided t test or χ2 test. RT use was summarized per year by frequency with 95% confidence intervals (CI). The association of RT receipt with sociodemographic and clinical variables was modeled using logistic regression.
resultsOf the AYAs included, 20.1% received RT, with a significant decline in RT use over time from 33.9% in 2004 to 9.3% in 2020 (P < 0.0001). Use of mantle RT declined over time from 40% in 2004 to 0% in 2018 (P < 0.0001). Female AYAs were consistently less likely to receive RT than males. Rural versus metro setting (OR, 1.69; 95% CI, 1.34-2.14; P < 0.0001) and private versus no insurance (OR, 1.58; 95% CI, 1.42-1.76; P < 0.0001) were associated with greater RT use.
conclusionsUse of RT in AYAs with Hodgkin lymphoma declined from 2004 to 2020, especially in female and uninsured AYAs. IMPACT: Whereas use of RT declined overall for AYAs with Hodgkin lymphoma, this was not equal across groups. Research is needed to better understand disparities in RT use by rurality and insurance status. See related In the Spotlight, p. 1445.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.